Epizyme has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Read the full story

Eisai and Merck announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab Read the full story

Evolva Holding announced that Emergent BioSolutions has acquired Evolva’s anti-bacterial programme, the EV-035 series Read the full story

Hikma Pharmaceuticals announces a pharma partnership with Eisai for the distribution of Fycompa. Read the full story

FSC Therapeutics has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex Sprinkle (rabeprazole sodium). Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Eisai is a top pharmaceutical company based in Tokyo, Japan Read the full story

Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen®. Read the full story

Eisai and Biogen Idec have entered into a pharma deal to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. Read the full story

Mylan Pharmaceuticals and pharma alliances, Banner Pharmacaps have entered into a settlement and license agreement with Eisai and Valeant Pharmaceuticals. Read the full story